$47MSeries B, 28 October 2025
Oversubscribed Series B advances lead oncology programs into Phase I and the AbReptor platform.
- Amount
- $47M
- Stage
- Series B
- Announced
- 28 October 2025
- Lead
- Korea Investment Partners
- Other investors
- SV Investment, DSC Investment, STIC Ventures, Smilegate Investment
- Use of funds
- Oversubscribed Series B advances lead oncology programs into Phase I and the AbReptor platform.
- Checked
- Amount and date matched across 2 press sources
- Sources
- Pinetree Therapeutics Raises $47 Million in Oversubscribed Series B to Advance Next-Generation Protein Degrade pulse2.com
Pinetree Therapeutics Raises $47 Million in Oversubscribed Series B to Advance Next-Generation Protein Degrade news.google.com